newsfilter
← Latest News
Business Wire·

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Prioritizing development of RP-A501 (Danon disease), RP-A601 (PKP2-ACM), and RP-A701 (BAG3-DCM) to advance AAV cardiovascular gene therapy platform for sustained value creation FDA RMAT designation awarded to RP-A601